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Plasma concentration and urinary excretion of N-terminal pro- atrial granules [1–3]. a-ANP regulates natriuresis and
atrial natriuretic peptides in patients with kidney diseases. diuresis through specific renal receptors by activation of
Background. Biologically active N-terminal fragments such the guanylate cyclase/cyclic guanosyl 3959 monophos-as proANP(1-30), proANP(31-67), and proANP(1-98) derive
phate (cGMP) system [2–4]. Recent studies have demon-from the prohormone of a-human atrial natriuretic peptide
strated that after proteolytic release of the C-terminal[proANP(99-126) or a-ANP]. No systematic data are available
for patients with different kidney diseases. a-ANP, presumably during the secretion from cardiac
Methods. Specific immunoassays were developed to deter- cells, the N-terminal proANP(1-98) is further degraded
mine plasma and urine concentrations of these fragments in in the heart and the circulation to render distinct peptide121 patients with different degrees of kidney function and
fragments, namely proANP(1-30), proANP(31-67), andurinary protein excretion, respectively.
proANP(79-98) [5, 6]. These fragments circulate in ani-Results. In patients with kidney disease and normal renal
function without proteinuria, circulating proANP(1-30) and mal species and healthy humans exhibiting circadian
proANP(31-67) increased 2.8-fold and 6.5-fold, respectively. variations inversely related to the levels of atrial blood
Urinary excretion of proANP(31-67) increased by a factor of
pressure [7]. Furthermore, it has been demonstrated that7.7 in these patients, whereas proANP(1-30) was not affected.
N-terminal fragments have biological functions that arePatients with impaired renal function had a dramatic increase
of urinary proANP(31-67) excretion even before serum creati- qualitatively similar to a-ANP [8–10]. No data are avail-
nine levels started to rise. The progression of renal failure able regarding the activity of proANP(1-98). Unlike the
caused a significant rise of circulating proANP(1-30) (4.3-fold) atria, the kidney appears to secrete an atriapeptin (AP)-
and proANP(31-67) (3.0-fold) compared with patients with
like protein that was detected in the cortical tubule frac-normal renal function. Urinary excretion of proANP peptides
tion [11]. It was further demonstrated that normal ratsignificantly increased, particularly when the serum creatinine
level was .5.0 mg/dL [proANP(1-30) 26-fold, proANP(31-67) kidney expresses ANP mRNA [12]. Urodilatin—proANP
8.4-fold]. Urinary excretion of proANP(1-30) increased up to (95-126)—is the renal analogue of a-ANP, differentially
4.4-fold and urinary excretion of proANP(31-67) increased up processed in the kidney and detected in only the urine.
to 2.4-fold in patients with proteinuria in excess of 3 g/24 h.
Urodilatin being synthesized in the distal tubular regionConclusions. Plasma concentrations and urinary excretion
may be transported as a paracrine factor to the collectingof proANP(1-30) and proANP(31-67) are affected by kidney
disease and function, but not by proteinuria per se. It is pro- duct, where it exerts its suppressing effect on the sodium
posed that the diseased kidney increases early urinary excretion reabsorption inducing diuresis and natriuresis [13, 14].
of proANP fragments to participate in the regulation of renal In particular, previous pharmacological studies havefunction as well as sodium and water excretion.
reported that proANP(31-67) promotes sodium excre-
tion and affects vasodilation in the rat [10], dog [15], and
human [16]. However, the mechanisms for the natriureticAtrial natriuretic peptide [proANP(99-126); a-ANP]
actions of proANP(31-67) are not completely defined. Itwas discovered as a cardiac hormone in which the 126
is suggested that the inhibition of the sodium-potassium-amino acid prohormone proANP(1-126) is stored in
ATPase in both the kidney medulla and cortex is medi-
ated by prostaglandin E2 [17]. A recently published ex-
perimental study in anesthetized dogs with a single intactKey words: renal disease, proteinuria, proANP(1-30), proANP(31-67),
atrial natriuretic peptide, body fluid balance, progressive renal disease. kidney [18] could show that sustained intrarenal infu-
sions of proANP(31-67) produced a 66% fall in reninReceived for publication June 2, 2000
secretion associated with significant increases in creati-and in revised form November 28, 2000
Accepted for publication December 1, 2000 nine clearance, renal blood flow, urine flow, and sodium
excretion. Thus, proANP(31-67) may represent an im-Ó 2001 by the International Society of Nephrology
1928
Franz et al: ProANP peptides in renal diseases 1929
portant hormonal mechanism involved in the regulation (normal serum creatinine and creatinine clearance) with-
out a loss of urinary protein. These individuals had poly-of body fluid balance.
Clinical studies on circulating N-terminal proANP cystic kidney disease or glomerulonephritis with com-
plete remission after immunosuppressive therapy.fragments have mainly focused on patients with cardiac
disorders. It was found that their plasma concentrations As a control group, 16 healthy volunteers from our
hospital staff with a mean 6 SD age of 36 6 10 yearscorrelated significantly with echocardiographic measure-
ments of left ventricular structure and performance, the (range 23 to 54) were studied. No drugs were taken
by these volunteers, except hormonal contraceptives byfunction of aortic and mitral valves, and mortality [19–22].
Our group has recently investigated the influence of peri- some females.
odic circulatory volume expansion on plasma concentra-
Analytical methodstions of different proANP fragments in a large group of
patients undergoing regular hemodialysis treatment [23]. Blood samples were obtained by puncture of an ante-
cubital vein after a supine rest of at least 10 minutes.It was found that circulating proANP fragments are in-
fluenced by a variety of factors such as end-stage renal All samples were collected in chilled tubes containing
ethylenediaminetetraacetic acid (EDTA) and aprotinin,disease, hemodialysis treatment per se, dialyzer mem-
brane material, cardiac dysfunction, and/or hypertension. immediately placed on ice, and centrifuged within 10
minutes. Plasma was separated and stored at 2708C untilN-terminal proANP fragments have been determined
mainly in the circulation. To date, urinary excretion of analysis. Urine samples of a 24-hour collected urine were
also stored at 2708C until analysis. Plasma and urineproANP peptides has been investigated only in healthy
humans [24] and dogs [25]. No systematic data are avail- concentrations of proANP(1-30) and proANP(31-67)
were determined by competitive and specific enzymeable about proANP fragments in nondialyzed patients
with renal disease. Therefore, the present study was per- immunoassays [26]. The detection limits were 2.5 and 10
pmol/L. Cross-reactivity with proANP(1-98) was 68%formed to evaluate proANP fragments in the plasma
and urine of 121 patients with different kidney diseases, and 108%, respectively, and no cross-reactivity was ob-
served with proANP(79-98) or proANP(99-128).different degrees of impairment of renal function, and
different degrees of urinary protein excretion as com-
Statistical analysispared with healthy controls.
Results are given as mean 6 SD. Statistical analyses
were performed using the Student t test of paired data
METHODS
when comparing differences between consecutive values
Patients in the same individuals. Differences between groups
were compared by unpaired t test. Simple correlationWe studied 121 patients, 63 women and 58 men, with
various renal diseases. Patient ages ranged from 18 to analysis was performed by one-way analysis of variance
(ANOVA). A P value less than 0.05 was considered88 years, with a mean 6 SD age of 54 6 16 years. The
etiology of kidney disease was membranous glomerulo- significant.
nephritis (N 5 12), rapid proliferative glomerulonephri-
tis (N 5 10), IgA nephritis (N 5 9), minimal change
RESULTS
glomerulonephritis (N 5 7), Henoch Scho¨nlein glomeru-
Plasma concentrations and urinary excretion oflonephritis (N 5 2), focal segmental glomerulosclerosis
proANP(1-30) and proANP(31-67) in patients with(N 5 9), diabetic nephropathy (N 5 15), hypertensive
renal disease but preserved renal functionnephropathy (N 5 8), analgesic nephropathy (N 5 8),
polycystic kidney disease (N 5 6), miscellaneous (N 5 In healthy volunteers (N 5 16), the plasma concentra-
tions of proANP(1-30) and proANP(31-67) varied be-18), or shrunken kidney of unknown etiology (N 5 17).
In all patients, blood was drawn for blood chemistry, tween 0.23 and 0.41 nmol/L. The urine concentrations
of proANP(1-30) and proANP(31-67) were 88 6 39 andand urine was collected at 24 hours for analysis. Forty-
three patients had a normal serum creatinine; in the 181 6 130 nmol/24 hours, respectively. In patients with
renal disease but preserved renal function and withoutremaining 78 patients, the serum creatinine level ranged
between 1.3 and 6.7 mg/dL. In 29 patients, serum creati- proteinuria (N 5 19), plasma levels of proANP(1-30)
were 2.8-fold (P , 0.001) and of proANP(31-67) werenine was between 1.3 and 2.5 mg/dL. In 39 patients, it
was between 2.5 and 5.0 mg/dL, and in 10 patients, serum 6.5-fold (P , 0.0001) higher than in the control group
(Fig. 1A). Urinary excretion of proANP(1-30) was notcreatinine was .5.0 mg/dL. Urinary protein loss was
,0.15 g/24 hours in 23 patients, between 0.15 and 1.0 different between both groups, but urinary proANP(31-
67) elimination was 7.7-fold (P , 0.0001) elevated asg/24 hours in 41 patients, between 1.0 and 3.0 g/24 hours
in 31 patients, and higher than 3.0 g/24 hours in 26 pa- compared with the control group (Fig. 1B). In the control
group, the mean plasma level of proANP(31-67) wastients. Overall, 19 patients had normal renal function
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Fig. 2. Plasma concentration (A) and urinary excretion (B) of two
different N-terminal fragments of the proatrial natriuretic peptide [pro-
Fig. 1. Plasma concentration (A) and urinary excretion (B) of two ANP(1-30) and proANP(31-67)] in patients with renal disease and
different N-terminal fragments of the proatrial natriuretic peptide [pro- normal serum creatinine (j, N 5 43), serum creatinine between 1.3
ANP(1-30) and proANP(31-67)] in patients with renal disease but and 2.5 mg/dL ( , N 5 29), serum creatinine between 2.5 and 5.0
preserved renal function and without proteinuria (j) as compared with mg/dL (h, N 5 39), and of those patients with a serum creatinine .5.0
healthy controls (h). The fragments were determined by radioimmuno- mg/dL ( , N 5 10). Data are mean 6 SD; *P , 0.004 and **P ,
assay as described in the Methods section. Data are mean 6 SD (N 5 0.0001 compared with patients with normal serum creatinine.
19); **P , 0.0001 compared with healthy controls (N 5 16).
slightly lower than proANP(1-30), whereas in the group tion significantly increased as soon as serum creatinine
levels exceeded 2.5 mg/dL and were distinctly higher whenof patients with renal disease, the mean plasma concen-
tration of proANP(31-67) was 1.7-fold higher than pro- serum creatinine levels were above 5.0 mg/dL (Fig. 2B).
Circulating proANP(1-30) maximally increased 4.3-fold,ANP(1-30). In both of the groups, the urine excretion
of proANP(31-67) was significantly higher than the urine and proANP(31-67) rose 3.0-fold. Urinary proANP(1-30)
excretion maximally increased up to 26-fold, whereas uri-excretion of proANP(1-30), twofold for the control
group (P , 0.006), but 13.8-fold for the group of patients nary proANP(31-67) elimination rose 8.4-fold in the group
of patients with serum creatinine levels over 5.0 mg/dL.with renal disease (P , 0.0001).
Plasma concentrations and urinary excretion of Plasma concentration and urinary excretion of
proANP(1-30) and proANP(31-67) in patients withproANP(1-30) and proANP(31-67) in patients with
renal disease and impaired renal function renal disease and different degrees of proteinuria
Plasma concentration and urinary excretion of pro-Plasma concentration and urinary excretion of pro-
ANP(1-30) and proANP(31-67) were determined in pa- ANP(1-30) and proANP(31-67) were determined in pa-
tients with renal disease according to their daily urinarytients with renal disease and different degrees of renal
failure according to the serum creatinine level (range protein excretion rates (range 0 to 20.3 g/24 hours). There
was no significant difference for circulating proANP(1-30)0.7 to 6.8 mg/dL). Figure 2 demonstrates that patients
with a serum creatinine in the normal range had the or proANP(31-67) whether the patients had no protein-
uria or were severely proteinuric (Fig. 3A). A signifi-lowest plasma concentrations and urinary excretion of
proANP(1-30) and proANP(31-67). Progression of renal cantly (P , 0.05) higher urinary excretion of proANP(1-
30) was found in patients when proteinuria exceeded 1.0failure was associated with a consecutive rise of plasma
proANP(1-30) and proANP(31-67) concentrations. How- g/24 h (Fig. 3B). Urinary excretion of proANP(31-67)
increased according to the rise of proteinuria, but theever, urinary proANP(1-30) and proANP(31-67) excre-
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Fig. 3. Plasma concentration (A) and urinary excretion (B) of two
Fig. 4. Plasma concentration (A) and urinary excretion (B) of twodifferent N-terminal fragments of the proatrial natriuretic peptide [pro-
different N-terminal fragments of the proatrial natriuretic peptide [pro-ANP(1-30) and proANP(31-67)] in patients with renal disease and
ANP(1-30) and proANP(31-67)] in patients with renal disease and normalurinary protein loss ,0.15 g/24 h (j, N 5 23), urinary protein loss
serum creatinine. Comparison between nonproteinuric (h, N 5 19) andbetween 0.15 and 1.0 g/24 h ( , N 5 41), urinary protein loss between
proteinuric patients (j, N 5 17). Data are mean 6 SD; P 5 NS.1.0 and 3.0 g/24 h (h, N 5 31), and of those patients with a urinary
protein loss of .3.0 g/24 h ( , N 5 26). Data are mean 6 SD; *P ,
0.05 compared with patients with urinary protein loss ,0.15 g/24 h.
protein loss was 0.1 6 0.1 g/24 hours in the nonproteinuric
group and 5.3 6 5.2 g/24 hours in the proteinuric groupdifference was not statistically significant until the uri-
(P , 0.0001). Circulating proANP(1-30) and proANP(31-nary protein loss was .5.0 g/24 h. (Fig. 3B). However,
67) did not differ between the two groups (Fig. 4A). Nopatients with proteinuria between 1.0 and 3.0 g/24 hours
significant difference was also found for urinary excretionand those with a urinary protein loss .5.0 g/24 hours
of proANP(1-30) and proANP(31-67) between the twohad significantly higher serum creatinine levels (2.9 6
groups (Fig. 4B).1.9 and 2.6 6 1.6 mg/dL) than patients with proteinuria
,1.0 g/24 hours and ,0.15 g/24 hours (2.3 6 1.5 and Correlations
1.7 6 0.9 mg/dL). Urinary excretion of proANP(1-30)
proANP(1-30) and proANP(31-67) in plasma and urine,increased by a maximum of 4.4-fold. Urinary excretion
and their correlation to serum creatinine levels and protein-of proANP(31-67) was elevated by a maximum of 2.4-
uria. Overall, there was a good correlation between plasmafold in the group of patients with proteinuria .3.0 g/24
concentrations of proANP(1-30) and proANP(31-67)hours.
(correlation coefficient R 5 0.9, P , 0.0001), as well as
Plasma concentration and urinary excretion of between their respective urinary excretion rates (R 5 0.8,
proANP fragments in patients with normal serum P , 0.0001). No correlation was found between circulating
creatinine: Nonproteinuric versus proteinuric patients proANP(1-30) and urinary excretion of proANP(1-30),
but circulating proANP(31-67) significantly correlatedFigure 4 shows plasma levels and urinary excretion of
with proANP(31-67) urine excretion (R 5 0.5, P ,proANP(1-30) and proANP(31-67) in patients with a
0.0001). The serum creatinine levels of the patients corre-normal serum creatinine value and urinary protein excre-
lated well with both plasma concentrations and urinarytion ,0.15 g/24 hours (N 5 19) as compared with
elimination of proANP(1-30) and proANP(31-67) (R be-patients with a normal serum creatinine value but protein-
uria .1.0 g/24 hours (N 5 17). Mean 6 SD urinary tween 0.4 and 0.6, P , 0.0001). However, urinary protein
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loss did not correlate with either plasma levels nor with quantitation of the relative amounts would be only possi-
ble if the major circulating peptides are unequivocallyurinary excretion of proANP(1-30) or proANP(31-67).
Plasma concentrations and urinary excretion of pro- identified.
We investigated 121 patients with renal disease andANP(1-30) and proANP(31-67) and their correlation to
urinary sodium excretion, systolic and diastolic blood different degrees of renal failure as well as different
degrees of urinary protein loss. In addition to the plasmapressure. Urinary sodium excretion did not correlate
with proANP(1-30) or proANP(31-67) in either plasma concentrations of proANP(1-30) and proANP(31-67),
we also determined their respective urinary excretionnor urine. Systolic blood pressure slightly correlated with
plasma proANP(31-67) concentration (R 5 0.3, P , 0.01) expressed as nmol/24 h. Since ANP is reportedly synthe-
sized in the kidneys [11, 12] and some of its forms mayand urinary excretion of proANP(1-30) (R 5 0.3, P ,
0.03), whereas diastolic blood pressure did not correlate have important autocrine or paracrine regulatory func-
tion [11], the urinary excretion of proANP fragmentswith either of the propeptides in plasma or urine. The
correlation between diastolic blood pressure and urinary seemed to be of interest.
The present study reveals that patients with renalsodium excretion was slightly significant (R 5 0.3, P ,
0.05), but not for the systolic blood pressure. disease but normal kidney function and no proteinuria
had significantly higher plasma concentrations of pro-
ANP(1-30) and proANP(31-67) than healthy controls
DISCUSSION
(Fig. 1A). Their urinary excretion of proANP(31-67)
Some fragments that derive from the N-terminus of was considerably elevated when compared with healthy
proANP, namely proANP(1-30) and proANP(31-67), subjects (Fig. 1B). Interestingly, the mean plasma con-
have been shown to exert biological functions qualita- centration of proANP(31-67) was only 1.7-fold higher
tively similar to the C-terminal a-ANP [8–10]. The major than the mean plasma concentration of proANP(1-30),
stimulus for prohormone synthesis and ANP release is as compared with a 13.8-fold higher urinary excretion
atrial stretch caused by volume overload [2–4]. It was of proANP(31-67) than that of proANP(1-30). It seems
shown that proANP(31-67) levels determined by radio- that in the diseased kidney, although renal function is
immunoassay were a better guide to small changes in normal, there are factors that determine proANP synthe-
salt and water metabolism than levels of a-ANP. In per- sis, specifically the renal clearance and degradation of
sons with chronic heart failure, serum levels of pro- the peptides.
ANP(31-67) were reportedly the most sensitive indicator None of the patients with normal renal function in our
of the degree of disease, allowing differentiation of indi- study had evidence for volume overload. Mean sodium
viduals in the New York Heart Association class I from excretion was 188 6 128 mmol/24 hours and was higher
normal healthy individuals [19–22]. Patients with end- compared with healthy controls (119 6 41 mmol/24
stage renal disease undergoing regular hemodialysis hours). Their mean arterial blood pressure was within
treatment have markedly increased plasma concentra- normal ranges (systolic blood pressure 127 6 15 mm Hg,
tions of proANP fragments [23]. Whereas hemodialysis diastolic blood pressure 80 6 9 mm Hg), but 6 out of
never corrects the defect in the metabolism of these pep- 19 patients received antihypertensive medication (5 pa-
tides [23], successful kidney transplantation decreases tients took 1 drug and 1 patient took 3 drugs). Schmid
the circulating levels of a-ANP, proANP(31-67), and et al investigated hypertensive patients with polycystic
proANP(1-98) within the first 24 hours after surgery, kidney disease who were on a low-sodium and high-
and the levels return to normal within 7 to 10 days [27]. sodium diet [28]; their natriuresis-blood pressure curve
However, until now there have been no systematic data showed an upward shift (resetting) and a positive slope
available that focus on proANP fragments in patients (sodium sensitivity) associated with an exaggerated re-
with different degrees of renal disease before hemodialy- sponse of ANP to sodium loading. The resetting of the
sis is instituted. Furthermore, as our assays are suitable natriuresis-blood pressure relationship and the increased
for different biological specimen, urinary excretion was blood pressure sensitivity to sodium was observed irre-
included in our studies. spective of whether the glomerular filtration rate was
Regarding the specificity of the immunoassays used, normal or reduced [28]. Another five patients were actu-
both also recognize proANP(1-98) and possibly other pep- ally treated with immunosuppressive agents. One patient
tides derived from this precursor as long they contain the received cyclophosphamide. Another patient was treated
respective epitopes from the regions (1-30) and (31-67). with cyclosporine, and three patients received low-dose
However, since the levels measured are not well corre- prednisone. Finally, the age of this patient population
lated, we conclude that the majority of the immunoreac- was significantly higher than in healthy controls (50 6
tive peptides are recognized in only one of the assays. 17 vs. 36 6 10 years, P , 0.001). Thus, we cannot exclude
Species that contain both epitopes and are measured in that factors such as hypertension, immunosuppressive
treatment, or the patients’ age could be responsible forboth assays represent only a small fraction. A detailed
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the observed elevated plasma concentrations and urinary by the respective serum creatinine level. According to
our findings, we assume that with the rise of circulatingexcretion of proANP peptides in patients with renal dis-
ease but normal kidney function. proANP fragments caused by progressive renal failure,
the diseased kidney may increase the clearance rate ofRitter, Needleman, and Greenwald demonstrated the
de novo synthesis of an atriapeptin (AP)-like protein these peptides and probably also synthesizes proANP
peptides in an attempt to increase diuresis.(AP126ir) in neonatal rat kidney cultures [11]. Unlike
the atria, kidney cells appear to secrete AP solely by In the present study, we further investigated whether
the amount of urinary protein loss determines plasmaconstitutive means. In primary adult rat kidney cultures,
most of the AP126ir was detected in the cortical tubule concentrations and urinary excretion of proANP pep-
tides. Proteinuria ranged between 0 and 20.3 g/24 hours,fraction, demonstrating that these cells could secrete
AP126ir. It was hypothesized that the renal AP may be but the amount of urinary protein loss did not signifi-
cantly affect the levels of circulating proANP fragmentsas important as an autocrine or paracrine regulator of
renal function [11]. Also, Greenwald et al demonstrated (Fig. 3A). Urinary excretion of proANP(1-30) signifi-
cantly increased when proteinuria was higher than 1.0that normal rat kidney expresses ANP mRNA [12]. This
study further substantiates the synthesis of ANP in the g/24 hours, and urinary excretion of proANP(31-67) was
significantly elevated when proteinuria exceeded 3.0 g/24mammalian kidney. Unlike the mammalian heart, the
kidney may contain two distinct ANP gene transcripts hours (Fig. 3B). This can be explained by differences in
renal function. In patients with normal serum creatinine,[12]. Our results support the hypothesis that proANP is
synthesized in the kidney and indicate that a renal ANP the amount of urinary protein loss did not significantly
relate to the plasma concentration or urinary excretionsecretion serves as an adaptive mechanism to preserve
renal function in kidney disease. of proANP(1-30) or proANP(31-67) (Fig. 4). Overall,
urinary protein loss did not correlate with any of theIn 1988, Winters et al demonstrated that chronic renal
failure was associated with significantly increased circula- proANP fragments in plasma or urine.
Although N-terminal fragments of the pro-ANP areting concentrations of proANP(1-30) and proANP(31-67)
compared with healthy controls [5]. However, the au- thought to have biological function such as natriuresis
and diuresis, the sodium excretion (mmol/day) of thethors have investigated 15 patients with high-grade renal
impairment only [5]. Our group recently published a study patients did not correlate with either proANP(1-30) or
proANP(31-67) excretion or with their respective plasmaon proANP peptides in a larger group of patients under-
going regular hemodialysis treatment [23]. We demon- concentrations. Systolic blood pressure was 137 6 20
mm Hg (mean 6 SD) and correlated slightly with plasmastrated that end-stage renal failure is associated with
increasing plasma concentrations of proANP(1-30) and levels of proANP(31-67) and urinary excretion of pro-
ANP(1-30). Diastolic blood pressure was 81 6 9 mm HgproANP(31-67) [23]. Our present study shows that with
the progression of renal failure the maximal relative in- (mean 6 SD) and did not correlate with any of the
proANP peptides. Diastolic blood pressure, however,crease was slightly higher for circulating proANP(1-30)
than for proANP(31-67) (4.3- vs. 3.0-fold). However, the showed a weak but significantly positive correlation to
urinary sodium excretion.highest plasma levels measured were much lower than
predialytic plasma concentrations of patients with end- In conclusion, plasma concentrations and urinary ex-
cretion of proANP(1-30) and proANP(31-67) are af-stage renal failure undergoing regular hemodialysis treat-
ment. The increase of urinary excretion of proANP(1-30) fected by renal failure, but not by proteinuria per se.
Other factors such as hypertension, immunosuppressiveand proANP(31-67) was not significant until serum creat-
inine exceeded 2.5 mg/dL (Fig. 2B). In patients with agents, and/or age of the patients also could affect plasma
and urinary proANP peptides. However, it is presumedhigh-grade renal failure (serum creatinine .5.0 mg/dL),
urinary excretion of proANP fragments was markedly that the diseased kidney increases urinary excretion of
proANP peptides to participate in the regulation of renalelevated, proANP(1-30) 26-fold, but proANP(31-67)
only 8.4-fold (Fig. 2B). In end-stage renal failure, the function and possibly to synthesize atrial natriuretic pro-
hormone. It is hypothesized that the early and dramaticincreased concentrations of circulating proANP frag-
ments in part may reflect reduced renal clearance. How- increase of circulating and excreted fragments of pro-
ANP in renal pathology and deteriorating renal functionever, we have demonstrated that simultaneously with
the rise of proANP fragments in the circulation, the might exert a mechanism of counter-regulation. These
peptides could actually compensate for vascular and re-respective urinary excretion also increased. Overall, we
found a highly positive correlation between the plasma nal effects of messengers like catecholamines, angioten-
sin, and endothelin, which all increase because of renalconcentrations of proANP(1-30) and proANP(31-67), as
well as between their urinary excretions. Plasma concen- pathology. This hypothesis seems reasonable, since it has
recently been shown that the administration of pro-trations and urinary excretion of proANP peptides were
also correlated to the degree of renal failure expressed ANP(31-67) helps to counter-regulate deteriorating re-
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